Special Protocol Assessment
-
Hospitals
Histogenics Corporation Announces Amendment to NeoCart® Phase 3 Clinical Trial Enrollment Criteria
WALTHAM, Mass., Dec. 21, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Extremities
TissueGene, Inc. Announces Special Protocol Assessment (SPA) Agreement with the Food and Drug Administration (FDA) for its Phase 3 Clinical Trial of Invossa™ for Patients Suffering from Osteoarthritis of the Knee
ROCKVILLE, Md., May 15, 2015 /PRNewswire/ — TissueGene, Inc. announced today that it has reached an agreement with the U.S. Food…
Read More »